$KNSA
Kiniksa Pharmaceuticals Ltd

2020 Q3 Form 10-Q Financial Statement

#000155837020012880 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.80M $8.430M $8.440M
YoY Change 39.96% 52.72% 94.92%
% of Gross Profit
Research & Development $31.42M $22.01M $30.85M
YoY Change 42.72% 6.66% 79.35%
% of Gross Profit
Depreciation & Amortization $649.0K $523.0K $508.0K
YoY Change 24.09% 5130.0% 4980.0%
% of Gross Profit
Operating Expenses $43.22M $30.45M $39.29M
YoY Change 41.95% 16.38% 82.48%
Operating Profit -$43.22M -$30.45M -$39.29M
YoY Change 41.95%
Interest Expense $50.00K $1.390M $1.720M
YoY Change -96.4% -14.2% 60.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$43.17M -$29.06M -$37.57M
YoY Change 48.55% 18.42% 83.6%
Income Tax $667.0K -$2.002M -$374.0K
% Of Pretax Income
Net Earnings -$43.84M -$27.06M -$37.19M
YoY Change 62.01% 10.85% 83.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$664.6K -$493.5K -$682.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $364.4M $258.7M $287.4M
YoY Change 40.86% -23.44% -19.99%
Cash & Equivalents $85.87M $69.02M $83.02M
Short-Term Investments $278.5M $189.9M $204.6M
Other Short-Term Assets $14.00M $9.600M $9.000M
YoY Change 45.83% 159.46% 91.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $378.4M $268.3M $296.5M
YoY Change 41.04% -21.43% -18.52%
LONG-TERM ASSETS
Property, Plant & Equipment $4.573M $8.600M $8.900M
YoY Change -46.83% 258.33% 2125.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $48.00K $4.800M $2.800M
YoY Change -99.0% 50.0% 211.11%
Total Long-Term Assets $6.000M $13.50M $11.60M
YoY Change -55.56% 141.07% 866.67%
TOTAL ASSETS
Total Short-Term Assets $378.4M $268.3M $296.5M
Total Long-Term Assets $6.000M $13.50M $11.60M
Total Assets $384.4M $281.8M $308.1M
YoY Change 36.41% -18.81% -15.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.925M $6.400M $9.300M
YoY Change -38.67% 36.17% 1450.0%
Accrued Expenses $19.48M $21.10M $20.70M
YoY Change -7.7% -9.83% -8.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.89M $27.60M $30.20M
YoY Change -9.81% -1.43% 30.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $957.0K $2.300M $2.800M
YoY Change -58.39% 1050.0% 1300.0%
Total Long-Term Liabilities $957.0K $2.300M $2.800M
YoY Change -58.39% 1050.0% 1300.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.89M $27.60M $30.20M
Total Long-Term Liabilities $957.0K $2.300M $2.800M
Total Liabilities $25.90M $29.90M $32.90M
YoY Change -13.36% 6.03% 41.2%
SHAREHOLDERS EQUITY
Retained Earnings -$463.8M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $358.5M $251.9M $275.2M
YoY Change
Total Liabilities & Shareholders Equity $384.4M $281.8M $308.1M
YoY Change 36.41% -18.81% -15.61%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$43.84M -$27.06M -$37.19M
YoY Change 62.01% 10.85% 83.57%
Depreciation, Depletion And Amortization $649.0K $523.0K $508.0K
YoY Change 24.09% 5130.0% 4980.0%
Cash From Operating Activities -$34.32M -$29.27M -$41.67M
YoY Change 17.25% 42.92% 132.53%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$440.0K $790.0K
YoY Change -97.73% -54.17% -443.48%
Acquisitions
YoY Change
Other Investing Activities -$149.7M $15.66M $40.57M
YoY Change -1055.68% -108.08% -155.06%
Cash From Investing Activities -$149.7M $15.21M $41.37M
YoY Change -1083.96% -107.81% -155.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 146.4M 50.00K 490.0K
YoY Change 292680.0% -106.58% -99.69%
NET CHANGE
Cash From Operating Activities -34.32M -29.27M -41.67M
Cash From Investing Activities -149.7M 15.21M 41.37M
Cash From Financing Activities 146.4M 50.00K 490.0K
Net Change In Cash -37.59M -14.01M 190.0K
YoY Change 168.31% -93.52% -99.71%
FREE CASH FLOW
Cash From Operating Activities -$34.32M -$29.27M -$41.67M
Capital Expenditures -$10.00K -$440.0K $790.0K
Free Cash Flow -$34.31M -$28.83M -$42.46M
YoY Change 19.01% 47.69% 140.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 knsa Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2019Q4 knsa Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2020Q3 knsa Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2019Q4 knsa Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2020Q3 knsa Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2019Q4 knsa Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2020Q3 knsa Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2019Q4 knsa Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
dei Entity Central Index Key
EntityCentralIndexKey
0001730430
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38492
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D0
dei Entity Registrant Name
EntityRegistrantName
Kiniksa Pharmaceuticals, Ltd.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1327726
dei Entity Address Address Line1
EntityAddressAddressLine1
Clarendon House
dei Entity Address Address Line2
EntityAddressAddressLine2
2 Church Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Hamilton
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
HM11
dei Entity Address Country
EntityAddressCountry
BM
dei City Area Code
CityAreaCode
808
dei Local Phone Number
LocalPhoneNumber
451-3453
dei Security12b Title
Security12bTitle
Class A Common Shares
dei Trading Symbol
TradingSymbol
KNSA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85874000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46928000
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
278521000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
186452000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14018000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8247000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
378413000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
241627000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4573000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6398000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1166000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1927000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
210000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
210000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
48000
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3000
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4372000
CY2020Q3 us-gaap Assets
Assets
384413000
CY2019Q4 us-gaap Assets
Assets
254534000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3925000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5693000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19475000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20415000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1492000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1697000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24892000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27830000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
955000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
957000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
326000
CY2020Q3 us-gaap Liabilities
Liabilities
25904000
CY2019Q4 us-gaap Liabilities
Liabilities
29111000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
822301000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
581467000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-463816000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356092000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
358509000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
225423000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384413000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
254534000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31419000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22014000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74644000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112115000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11799000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8432000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29821000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25267000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
43218000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
30446000
us-gaap Operating Expenses
OperatingExpenses
104465000
us-gaap Operating Expenses
OperatingExpenses
137382000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43218000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30446000
us-gaap Operating Income Loss
OperatingIncomeLoss
-104465000
us-gaap Operating Income Loss
OperatingIncomeLoss
-137382000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
49000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1386000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1104000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4919000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43169000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29060000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103361000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-132463000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
667000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2002000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4363000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2393000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-43836000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-27058000
us-gaap Net Income Loss
NetIncomeLoss
-107724000
us-gaap Net Income Loss
NetIncomeLoss
-130070000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65958513
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54831308
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59754495
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53767003
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-43836000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-27058000
us-gaap Net Income Loss
NetIncomeLoss
-107724000
us-gaap Net Income Loss
NetIncomeLoss
-130070000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
66000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-39000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-27000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
66000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43839000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27097000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-107751000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-130004000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
225423000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2414000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4209000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26419000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
205834000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2936000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4851000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-231000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-37469000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
250416000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
331000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5558000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-43836000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
358509000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
279267000
CY2019Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
7000000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2893000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-65821000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
306519000
CY2019Q2 knsa Stock Issued During Period Value Milestone Payments
StockIssuedDuringPeriodValueMilestonePayments
1800000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
512000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3464000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
93000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37191000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
275197000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3758000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
630000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-27058000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
251911000
us-gaap Profit Loss
ProfitLoss
-107724000
us-gaap Profit Loss
ProfitLoss
-130070000
us-gaap Depreciation
Depreciation
1838000
us-gaap Depreciation
Depreciation
1502000
us-gaap Share Based Compensation
ShareBasedCompensation
14618000
us-gaap Share Based Compensation
ShareBasedCompensation
10115000
knsa Issuance Of Stock For Acquisition
IssuanceOfStockForAcquisition
8800000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-23000
knsa Noncash Lease Expense
NoncashLeaseExpense
761000
knsa Noncash Lease Expense
NoncashLeaseExpense
919000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
239000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3044000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4321000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3411000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5768000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2391000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1704000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4504000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-969000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2685000
knsa Increase Decrease In Accrued Milestone
IncreaseDecreaseInAccruedMilestone
-14850000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1105000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-916000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
943000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95341000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-134199000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
228000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1207000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
344159000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
406135000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
252300000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
454640000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92087000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47298000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
976000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
118000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5681000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
746000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
226374000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83734000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
38946000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3167000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47138000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72186000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86084000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69019000
us-gaap Income Taxes Paid
IncomeTaxesPaid
482000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1727000
knsa Deferred Offering Costs Included In Accrued Expenses And Accounts Payable
DeferredOfferingCostsIncludedInAccruedExpensesAndAccountsPayable
154000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
371000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common shares and share-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p>
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-463816000
us-gaap Net Income Loss
NetIncomeLoss
-107724000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95341000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
364395000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;font-style:italic;font-weight:bold;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">The Company reclassified certain prior year balances on its consolidated statements of cash flows to conform to current year presentation. The balances related to prepaid expenses and other assets and non-cash lease expense. The reclassifications had no effect on net cash used by operating activities or the Company’s consolidated statements of operations and comprehensive loss.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. At September 30, 2020 and December 31, 2019, substantially all of the Company’s cash, cash equivalents and short-term investments were held at two financial institutions. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash, cash equivalents and short-term investments and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
CY2020Q3 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
210000
CY2019Q4 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
210000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2019Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2019Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2019Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2020Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2020Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
knsa Number Of Securities
NumberOfSecurities
11
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
78056000
CY2019 knsa Number Of Securities
NumberOfSecurities
7
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
43107000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8736000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8723000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4163000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2325000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4573000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6398000
CY2020Q3 us-gaap Depreciation
Depreciation
649000
CY2019Q3 us-gaap Depreciation
Depreciation
523000
us-gaap Depreciation
Depreciation
1838000
us-gaap Depreciation
Depreciation
1502000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
341000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
340000
us-gaap Operating Lease Cost
OperatingLeaseCost
1022000
us-gaap Operating Lease Cost
OperatingLeaseCost
1102000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
30000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
52000
us-gaap Variable Lease Cost
VariableLeaseCost
132000
us-gaap Variable Lease Cost
VariableLeaseCost
161000
CY2020Q3 us-gaap Lease Cost
LeaseCost
371000
CY2019Q3 us-gaap Lease Cost
LeaseCost
392000
us-gaap Lease Cost
LeaseCost
1154000
us-gaap Lease Cost
LeaseCost
1263000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0716
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
455000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1124000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1593000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
46000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1547000
CY2020Q3 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
10333000
CY2019Q4 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11813000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6747000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7089000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1621000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1087000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
774000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19475000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20415000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0169
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0056
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0213
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M26D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M26D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M15D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8258
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8102
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7924
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5558000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3758000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14618000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10115000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-43836000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-27058000
us-gaap Net Income Loss
NetIncomeLoss
-107724000
us-gaap Net Income Loss
NetIncomeLoss
-130070000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65958513
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54831308
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59754495
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53767003
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10439647
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8635968
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2019Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2019Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2020Q3 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2019Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2019Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2020Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2020Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
667000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4363000
CY2020Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
5463000

Files In Submission

Name View Source Status
0001558370-20-012880-index-headers.html Edgar Link pending
0001558370-20-012880-index.html Edgar Link pending
0001558370-20-012880.txt Edgar Link pending
0001558370-20-012880-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
knsa-20200930.xsd Edgar Link pending
knsa-20200930x10q.htm Edgar Link pending
knsa-20200930x10q_htm.xml Edgar Link completed
knsa-20200930xex31d1.htm Edgar Link pending
knsa-20200930xex31d2.htm Edgar Link pending
knsa-20200930xex32d1.htm Edgar Link pending
knsa-20200930xex32d2.htm Edgar Link pending
knsa-20200930_cal.xml Edgar Link unprocessable
knsa-20200930_def.xml Edgar Link unprocessable
knsa-20200930_lab.xml Edgar Link unprocessable
knsa-20200930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending